МАССИВНОЕ ОПУХОЛЕВОЕ ПОРАЖЕНИЕ («TUMOR BURDEN») ПРИ ЛИМФОМЕ ХОДЖКИНА КАК ФАКТОР ПРОГНОЗА ЗАБОЛЕВАНИЯ У ЛИЦ МОЛОДОГО ВОЗРАСТА
Аннотация
Об авторе
А. П. Карицкий
ФГБУ «НИИ онкологии им. Н.Н. Петрова» Минздрава России, г. Санкт-Петербург
Россия
197758, г. Санкт-Петербург, п. Песочный, ул. Ленинградская, 68
Россия
197758, г. Санкт-Петербург, п. Песочный, ул. Ленинградская, 68
Список литературы
1. Кулева С.А. Современные подходы к лечению лимфомы Ходжина у детей // Детская онкология. 2009. № 3–4. С. 41–46.
2. Кулева С.А., Колыгин Б.А. Прогностические факторы и прогностические модели при лимфоме Ходжкина у детей и подростков // Вопросы онкологии. 2010. Т. 56, № 3. С. 272–277.
3. Böll B., Görgen H., Fuchs M., Pluetschow A., Eich H.T., Bargetzi M.J., Weidmann E., Junghanß C., Greil R., Scherpe A., Schmalz O., Eichenauer D.A., von Tresckow B., Rothe A., Diehl V., Engert A., Borchmann P. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study GroupHD10 and HD11 trials // J. Clin. Oncol. 2013. Vol. 31 (12). P. 1522–1529. doi: 10.1200/ JCO.2012.45.4181.
4. Dann E.J., Bar-Shalom R., Tamir A., Haim N., Ben-Shachar M., Avivi I., Zuckerman T., Kirschbaum M., Goor O., Libster D., Rowe J.M., Epelbaum R. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome // Blood. 2007. Vol. 109 (3). P. 905–909.
5. Edwards-Bennett S.M., Jacks L.M., Moskowitz C.H., Wu E.J., Zhang Z., Noy A., Portlock C.S., Straus D.J., Zelenetz A.D., Yahalom J. Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience // Ann. Oncol. 2010. Vol. 21 (3). P. 574–581. doi: 10.1093/annonc/mdp337.
6. Eich H.T., Müller R.P.,Ansén S., Josting A., Engert A., Hansemann K., Pfistner B., Wolf J., Willich N., Diehl V. New therapeutic strategies for Hodgkin lymphoma in cooperation of radiation oncology and medical oncology // Rontgenpraxis. 2003. Vol. 55 (3). P. 114–124.
7. Fermé C., Sebban C., Hennequin C., Diviné M., Lederlin P., Gabarre J., Ferrant A., Caillot D., Bordessoule D., Brice P., Moullet I., Berger F., Lepage E. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin’s disease: results of the groupe d’études des lymphomes de l’Adulte H89 trial // Blood. 2000. Vol. 95 (7). P. 2246–2252.
8. Fermé C., Mounier N., Casasnovas O., Brice P., Divine M., Sonet A., Bouafia F., Bastard-Stamatoullas A., Bordessoule D., Voillat L., Reman O., Blanc M. Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte (GELA) // Blood. 2006. Vol. 107 (12). P. 4636–4642.
9. Ferme C., Mounier N., Diviné M. Current clinical trials for the treatment of adult advanced-stage Hodgkin’s disease: GELA experiences // Ann. Oncol. 2002. Vol. 1. P. 96–97.
10. Ganz P.A., Moinpour C.M., Pauler D.K., Kornblith A.B., Gaynor E.R., Balcerzak S.P., Gatti G.S., Erba H.P., McCoy S., Press O.W., Fisher R.I. Health status and quality of life in patients with early-stage Hodgkin’s disease treated on Southwest Oncology Group Study 9133 // J. Clin. Oncol. 2003. Vol. 21 (18). P. 3512–3519.
11. Gobbi P.G., Comelli M., Grignani G.E., Pieresca C., Bertoloni D., Ascari E. Estimate of expected survival at diagnosis in Hodgkin’s disease: a means of weighting prognostic factors and a tool for treatment choice and clinical research. A report from the International Database on Hodgkin’s Disease (IDHD) // Haematologica. 1994. Vol. 79. P. 241–255.
12. Gobbi P.G., Ghirardelli M.L., Solcia M., Giulio G.D., Merli F., Tavecchia L., Berte R., Davini O., Levis A., Broglia C., Maffe G.C., Llariucci F., Dare R., Ascari E. Image-aided estimate of tumor burden in Hodgkin’s disease: evidence of its primary prognostic importance // J. Clin. Oncol. 2001. Vol. 19. P. 1388–1394.
13. Hasenclever D., Diehl V. A prognostic score to predict tumor control in advanced Hodgkin’s disease // N. Engl. J. Med. 1998. Vol. 339. P. 1506–1514.
14. Horning S.J. Risk, cure and complications in advanced Hodgkin disease // Hematology Am. Soc. Hematol. Educ. Program. 2007. P. 197–203.
15. Hutchings M., Mikhaeel N.G., Fields P.A., Nunan T., Timothy A.R. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma // Ann. Oncol. 2005. Vol. 16 (7). P. 1160–1168.
16. Klimm B., Goergen H., Fuchs M., von Tresckow B., Böll B., Meissner J., Glunz A., Diehl V., Eich H.T., Engert A., Borchmann P. Impact of risk factors on outcomes in early-stage Hodgkin’s lymphoma: an analysis of international staging definitions // Ann. Oncol. 2013. Vol. 24 (12). P. 3070–3076. doi: 10.1093/annonc/mdt413
17. Kulyova S.A., Kochurova N.V., Kolygin B.A. DAL-HD as a riskadapted treatment of children with Hodgkin’s lymphoma // HAEMA. 2006. Vol. 8 (1). P. 98–104.
18. Mauch P.M., Kalish L.A., Kadin M., Coleman C.N., Osteen R., Hellman S. Pattern of presentation of Hodgkin’s disease // Cancer. 1993. Vol. 71. P. 2062–2071.
19. Meyer R.M., Gospodarowicz M.K., Connors J.M., Pearcey R.G., Bezjak A., Wells W.A., Burns B.F., Winter J.N., Horning S.J., Dar A.R., Djurfeldt M.S., Ding K., Shepherd L.E. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group // J. Clin. Oncol. 2005. Vol . 23 (21). P. 4634–4642.
20. Noordijk E.M.,Carde P.,Mandard A.M.,Mellink W.A.,Monconduit M., Eghbali H., Tirelli U., Thomas J., Somers R., Dupouy N. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin’s disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-MarieCurie // Ann Oncol. 1994. Vol. 5. Suppl. 2. P. 107–112.
21. Radford J.A., Rohatiner A.Z., Ryder W.D., Deakin D.P., Barbui T., Lucie N.P., Rossi A., Dunlop D.J., Cowan R.A., Wilkinson P.M., Gupta R.K., James R.D., Shamash J., Chang J., Crowther D., Lister T.A. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin’s disease // J. Clin. Oncol. 2002. Vol. 20 (13). P. 2988–2994.
22. Raemaekers J.M. Questions concerning supplementary radiotherapy in patients with stage III or IV Hodgkin’s disease in remission after chemotherapy // Ned. Tijdschr. Geneeskd. 1997. Vol. 141 (26). P. 1285–1289.
23. Sieber M., Tesch H., Pfistner B., Rueffer U., Paulus U., Munker R., Hermann R., Doelken G., Koch P., Oertel J., Roller S., Worst P., Bischof H., Glunz A., Greil R., von Kalle K., Schalk K.P., Hasenclever D., Brosteanu O., Duehmke E., Georgii A., Engert A., Loeffler M., Diehl V., Mueller R.P., Willich N., Fischer R., Hansmann M.L., Stein H., Schober T., Koch B. Treatment of advanced Hodgkin’s disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin’s Lymphoma Study Group HD6 trial // Ann. Oncol. 2004. Vol. 15 (2). P. 276–282.
24. Specht L. Tumor burden as the main indicator of prognostic in Hodgkin’s disease // Eur. J. Cancer. 1992. Vol. 28. P. 1982–1985.
25. Specht L., Lauritzen A.F., Nordentoft A.M., Andersen P.K., Christensen B.E., Hippe E., Hou-Jensen K., Nissen N.I. Tumor cell concentration and tumor burden in relation to histopathologic subtype and other prognostic factors in early stage Hodgkin’s disease. The Danish National Hodgkin Study Group // Cancer. 1990. Vol. 65. P. 2594–2601.
26. Straus D.J., Gaynor J.J., Myers J., Merke D.P., Caravelli J., Chapman D., Yahalom J., Clarkson B.D. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin’s disease treated with alternating potentially non-cross-resistant chemotherapy and intermediate-dose radiation therapy // J. Clin. Oncol. 1990. Vol. 7. P. 1173–1186.
27. Viviani S., Bonadonna G., Santoro A., Bonfante V., Zanini M., Devizzi L., Soncini F., Valagussa P. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease: ten-year results // J. Clin. Oncol. 1996. Vol. 14 (5). P. 1421–1430.
28. Zekri J.M., Mouncey P., Hancock B.W. Trials in advanced Hodgkin’s disease: more than 30 years experience of the British National Lymphoma Investigation // Clin. Lymphoma. 2004. Vol. 5 (3). P. 174–183.
29. Zweig, M.H., Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine // Clin. Chemistry. 1993. Vol. 39. P. 561–577.
Рецензия
Для цитирования:
Карицкий А.П. МАССИВНОЕ ОПУХОЛЕВОЕ ПОРАЖЕНИЕ («TUMOR BURDEN») ПРИ ЛИМФОМЕ ХОДЖКИНА КАК ФАКТОР ПРОГНОЗА ЗАБОЛЕВАНИЯ У ЛИЦ МОЛОДОГО ВОЗРАСТА. Сибирский онкологический журнал. 2014;(4):16-24.
For citation:
Karitsky A.P. MASSIVE TUMOR BURDEN IN HODGKIN’S LYMPHOMA AS A PROGNOSTIC FACTOR IN YOUNG ADULTS. Siberian journal of oncology. 2014;(4):16-24. (In Russ.)
Просмотров: 3166
.png)
Послать статью по эл. почте 
